Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Glioblastoma 3Advanced Solid Tumours 3Solid Tumors 2Advanced Malignant Solid Neoplasm 2Triple-negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Rhabdomyosarcoma 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Pinealoma 1Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Myelodysplastic-Myeloproliferative Diseases 1Metastatic Pancreatic Adenocarcinoma 1Medulloblastoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Laryngeal Neoplasms 1Gliosarcoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Chromosome 5q Deletion Syndrome 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Astrocytoma 1

Interventions

Temozolomide 6Cyclophosphamide 4antineoplaston AS 2-1 3antineoplaston A10 3Radiotherapy 3Filgrastim 3sargramostim 2aldesleukin 2Vincristine 2Thalidomide 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Irinotecan 2Donepezil 2Cisplatin 2Carmustine 2Bevacizumab 2veliparib 1trametinib 1temsirolimus 1surufatinib 1spartalizumab 1sonidegib 1ribociclib 1reolysin 1plerixafor 1ganitumab 1fosbretabulin 1entinostat 1dactolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neuroectodermal Tumors, Primitive × adavosertib × Clear all
NCT02095132 2023-09-26

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Completed
76 enrolled 25 charts
CNSSarcoma

Medulloblastoma, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡